Objectives: Oxidative stress biomarkers as reactive oxygen species are induced by the sustained activation of neutrophils and other CF-derived defects in the lung of CF patients. Observed defects include an impaired glutathione (GSH) metabolism. Its supplementation may counterbalance the oxidative stress. A randomized, single blind controlled trial of inhaled GSH versus placebo (NCT01450267) is underway in order to evaluate the effect of GSH in cohort of CF patients. We report preliminary data on tolerability to GSH in a pediatric subset of enrolled patients. Methods: 48 CF patients (F 23, age M±DS 13.53 yrs), in regular follow up at the Regional Pediatric CF Center of Naples, were enrolled for RCT. The main inclusion criteria were: CF diagnosis by sweat test and/or two CF causing mutations, age of patients >6 yrs, FEV1% >40% of the predicted value, negative culture for Burkholderia cepacia. Spirometry was performed before and 10 and 60 minutes after GSH inhalation test (10 mg/kg, maximum dosage 600 mg/dose) in order to assess tolerability. Conclusions: No patients showed a decrease in FEV1% >15% after GSH inhalation as defined in the study design. A statistically significant increase was observed for FEF25−75% after 10 and 60 minutes from inhalation (FEF 25−75 M±DS: T 0 71.64±33.35 VS T 10 76.37±36.73; p < 0.02 and T 0 71.64±33.35 VS T 60 : 80.26±35.25; p < 0.0001) and for FEV1% after 60 minutes from inhalation (FEV 1 M±DS: T 0 97.90±21.03 VS T 60 100.01±19.42; p < 0.01). No side effects were reported. On the basis of these preliminary results we are currently evaluating the efficacy of inhaled GSH on pulmonary function and inflammatory markers within a 12 months therapy.
The importance of biofilms in chronic human disease is increasingly recognised in modulating the local immune response and reducing the efficiacy of conventional antimicrobial therapies. We have previously shown, using scanning electron and confocal laser scanning microscopy, that the clinically safe alginate oligomer OligoG disrupts Pseudomonas aeruginosa PAO1 biofilm formation. The ability of OligoG to affect established biofilms was quantified using atomic force microscopy (AFM) to map differences in the mechanical properties of biofilm surfaces. Dried biofilms were imaged in air using tapping mode operation with silicon nitride noncontact cantilevers. AFM imaging and force measurements demonstrated obvious differences in the surface mechanical characteristics of the OligoG-treated and untreated biofilms. OligoG-treated biofilms exhibited significantly lower Young's moduli, and hence were less mechanically robust than the untreated biofilm (p < 0.05). When treated and untreated biofilms were subject to a controlled hydrodynamic shear, the remaining biofilms had significant differences in surface roughness as measured from AFM images (35.2±7.6 nm vs 12.1±5.4 nm). These studies demonstrate the utility of AFM as a quantitative approach to investigate, at the nanoscale, the interaction of potential therapies on biofilm structures. They also show the potential ability for OligoG treatment to modulate biofilm structure and maintenance in vivo.
